Menu
Back to Journals » Drug Design, Development and Therapy » Volume 12
Involvement of NF-κB and HSP70 signaling pathways in the apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens [Corrigendum] [Retraction]
Authors Ibrahim MY, Mohd Hashim N, Mohan S, Mohd Ali H, Abdelwahab S, Kamalidehghan B, Ghaderian M, Dehghan F, Salim LZ, Karimian H, Yahayu M, Ee Cheng Lian G, Abdulla M, Farjam AS
Received 8 March 2018
Accepted for publication 8 March 2018
Published 13 March 2018 Volume 2018:12 Pages 533—534
Ibrahim MY, Hashim NM, Mohan S, et al. Involvement of NF-κB and HSP70 signaling pathways in the apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens [Corrigendum]. Drug Des Devel Ther. 2015;9:3001–3002 was published subsequent to Ibrahim MY, Hashim NM, Mohan S, et al, Involvement of NF-ΚB and HSP70 signaling pathways in the apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens. Drug Des Devel Ther. 2014;8:2193–2211, and Ibrahim MY, Hashim NM, Mohan S, et al, α-Mangostin from Cratoxylum arborescens demonstrates apoptogenesis in MCF-7 with regulation of NF-κB and Hsp70 protein modulation in vitro, and tumor reduction in vivo. Drug Des Devel Ther. 2014;8:1629–1647.
When comparing the papers it becomes apparent that they have an unacceptably high degree of similarity and re-use. Further, there is no clear scientific distinction between the cell lines and the results in both. Accordingly, the Editor-in-Chief and Publisher issued a Notice of Retraction for Ibrahim MY, Hashim NM, Mohan S, et al, Involvement of NF-ΚB and HSP70 signaling pathways in the apoptosis of MDA-MB-231 cells induced by a prenylated xanthone compound, α-mangostin, from Cratoxylum arborescens. Drug Des Devel Ther. 2014;8:2193–2211 and the subsequent Corrigendum.
This retraction relates to this Corrigendum
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.